Tonix Pharmaceuticals Stock (TNXP) Hits A New All-Time Low: What's Going On?
Tonix Pharmaceuticals Stock (TNXP) Hits A New All-Time Low: What's Going On?
Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) shares traded lower by 7.2% to $0.17 Monday morning, hitting a new-all time low. The stock is trading lower on downward momentum after the company last week announced the pricing of a $4.4 million registered direct offering.
週一上午，Tonix製藥控股公司（納斯達克股票代碼：TNXP）股價下跌7.2％，至0.17美元，創歷史新低。該公司上週宣佈了440萬美元註冊直接發行的定價後，該股在下跌勢頭下跌。
Tonix has initiated a securities purchase agreement with existing healthcare-focused institutional investors for the sale of 14,666,666 shares of its common stock and accompanying warrants in a registered direct offering at a combined price of $0.30 per share.
Tonix已與現有以醫療保健爲重點的機構投資者啓動了證券購買協議，以註冊直接發行的形式出售14,666,666股普通股和附帶的認股權證，總價格爲每股0.30美元。
The offering, expected to close around April 1, is anticipated to generate gross proceeds of approximately $4.4 million. The net proceeds will be allocated towards working capital, general corporate purposes, and partial repayment of debt. A.G.P./Alliance Global Partners is the sole placement agent for the offering.
此次發行預計將於4月1日左右結束，預計將產生約440萬美元的總收益。淨收益將用於營運資金、一般公司用途和部分債務償還。A.G.P./Alliance Global Partners是本次發行的唯一配售代理人。
In addition to the offering, the company has agreed to amend certain existing warrants issued in 2023, reducing their exercise price to $0.33 per share and extending their termination dates.
除此次發行外，該公司還同意修改2023年發行的某些現有認股權證，將其行使價降至每股0.33美元，並延長其終止日期。
These amendments are contingent upon shareholder approval, and if not obtained within six months of the offering's closing, the warrants will have an exercise price equal to the Nasdaq minimum price.
這些修正案取決於股東的批准，如果在發行結束後的六個月內沒有獲得認股權證，則認股權證的行使價將等於納斯達克的最低價格。
China's March Manufacturing Growth Could 'Dump Into Global Markets, Thus Triggering Deflation,' Expert Warns
專家警告說，中國3月份的製造業增長可能 “傾向全球市場，從而引發通貨緊縮”
Should I Sell My TNXP Stock?
我應該賣掉我的TNXP股票嗎？
When deciding to hold on to or sell a stock, investors should consider their time horizon, unrealized gains and total return.
在決定持有或出售股票時，投資者應考慮其時間範圍、未實現收益和總回報。
Shares of Tonix Pharmaceuticals have decreased by 94.6% in the past year. An investor who bought shares of Tonix Pharmaceuticals at the beginning of the year would take a loss of $0.22 per share if they sold it today. The stock has fallen 48.56% over the past month, meaning an investor who bought shares on Mar. 1 would see a capital loss of $0.18.
在過去的一年中，Tonix Pharmicals的股價下跌了94.6％。年初購買Tonix Pharmicals股票的投資者如果今天出售，則每股虧損0.22美元。該股在過去一個月中下跌了48.56％，這意味着在3月1日購買股票的投資者將遭受0.18美元的資本損失。
Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Tonix Pharmaceuticals stock currently has an RSI of 12.61, indicating oversold conditions.
投資者也可以考慮市場動態。相對強弱指數可用於表明股票是超買還是超賣。Tonix Pharmicals股票目前的相對強弱指數爲12.61，這表明存在超賣情況。
For access to advanced charting and analysis tools and stock data, check out Benzinga PRO. Try it for free.
要訪問高級製圖和分析工具以及股票數據，請查看 Benzinga PRO。免費試用。
TNXP has a 52-week high of $3.80 and a 52-week low of $0.17.
騰訊智浦的52周高點爲3.80美元，52周低點爲0.17美元。
譯文內容由第三人軟體翻譯。